NCT03345290: PACTEP

Impact of the Central Blood Pressure Level in Cerebral Metabolic Aging: a 18F-FDG PET Study.

Completed NA Last updated 24 August 2022

What this trial tests

NA trial testing PET with a cerebral step in Aging Disorder in 92 participants. Completed in 6 November 2020.

Timeline

31 July 2018

Primary endpoint
6 November 2020

6 November 2020

Quick facts

Lead sponsor	Central Hospital, Nancy, France
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	prevention
Enrollment	92
Start date	31 July 2018
Primary completion	6 November 2020
Estimated completion	6 November 2020
Sites	1 location across France

Drugs / interventions tested

• PET with a cerebral step
• Central blood pressure measurement
• Neurocognitive tests

Conditions studied

• Aging Disorder — all drugs for Aging Disorder →

Sponsor

Central Hospital, Nancy, France

Who can join

18 and older, any sex, with Aging Disorder. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Cerebral glycolytic metabolism can be quantified by quantitative analysis of 18F-Fluorodeoxyglucose (18F-FDG) Positron Emission Tomography (PET). This allows to identify neurological diseases at an early stage of functional abnormalities, before any anatomical lesions, and to differentiate them from the "normal" brain aging. Aging mainly leads to atrophy with a decrease in cerebral metabolism in the prefrontal cortex, with consequent deterioration of cognitive processes, in particular executive functions (5).

In a population of 92 "control" subjects, investigators have already quantified the importance of the aging in frontal cortex hypometabolism. These patients were referred for a 18F-FDG PET in the follow-up of lymphoma considered to be in complete remission (PET without cerebral step), without any chemoradiotherapy within 2 months and with normal neuropsychological tests (Mini Mental State Examination, MMSE, Mini International Neuropsychiatric Interview MINI and Frontal Assessment Battery FAB).

However, cerebral aging can be "accelerated" by vascular risk factors, including increased central blood pressure, as investigators have recently reported in a pilot study involving elderly patients. This central pressure, which is directly linked to the cerebral micro-vascularization, can be easily measured by applanation tonometry. In this pilot study, investigators showed that a central pulse pressure equal or greater than 50 mmHg was associated with a significant frontal hypometabolism in elderly patients. This confirmed, at a stage of pre-clinical remodeling, the worse prognostic significance for this criterion, as reported in large epidemiological studies (increased risk of stroke and cardiac vascular events).

However, it is not yet known whether the level of central blood pressure interfere with the brain metabolism of younger subjects, especially with regard to aging observed throughout life. If this hypothesis is confirmed, preventive therapeutic strategies for accelerated aging, could thus integrate the monitoring of central pressure and cerebral metabolism.

The objective of this study is to determine, in a population of control subjects and on a larger scale, the impact of central blood pressure on brain metabolic aging , by using 18F-FDG PET.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

1. Brain ¹⁸F-FDG PET imaging in outpatients with post-COVID-19 conditions: findings and associations with clinical characteristics.
   Goehringer F, Bruyere A, Doyen M, Bevilacqua S, et al · · 2023 · cited 34× · PMID 36322190 · DOI 10.1007/s00259-022-06013-2
2. The pons as reference region for intensity normalization in semi-quantitative analysis of brain ¹⁸FDG PET: application to metabolic changes related to ageing in conventional and digital control databases.
   Verger A, Doyen M, Campion JY, Guedj E. · · 2021 · cited 29× · PMID 33761019 · DOI 10.1186/s13550-021-00771-0
3. Interactions Between Brain ¹⁸F-FDG PET Metabolism and Hemodynamic Parameters at Different Ages of Life: Results From a Prospective Cross-Sectional Study.
   Zimmermann G, Joly L, Schoepfer P, Doyen M, et al · · 2022 · cited 7× · PMID 35837479 · DOI 10.3389/fnagi.2022.908063
4. Effect of Point Spread Function Deconvolution in Reconstruction of Brain ¹⁸F-FDG PET Images on the Diagnostic Thinking Efficacy in Alzheimer's Disease.
   Doyen M, Mairal E, Bordonne M, Zaragori T, et al · · 2021 · cited 5× · PMID 34395486 · DOI 10.3389/fmed.2021.721551
5. Clinical impact of digital and conventional PET control databases for semi-quantitative analysis of brain ¹⁸F-FDG digital PET scans.
   Mairal E, Doyen M, Rivasseau-Jonveaux T, Malaplate C, et al · · 2020 · cited 4× · PMID 33258085 · DOI 10.1186/s13550-020-00733-y
6. Mild cognitive dysfunction in hereditary spastic paraplegia 4 disease related to fluorodesoxyglucose cerebral positron emission tomography.
   Miroglio R, Hocquel A, Ravel JM, Clément G, et al · · 2025 · cited 1× · PMID 41180955 · DOI 10.1093/braincomms/fcaf382
7. Reorganization of brain connectivity in post-COVID condition: a <sup>18</sup>F-FDG PET study.
   Verger A, Doyen M, Heyer S, Goehringer F, et al · · 2025 · PMID 40158051 · DOI 10.1186/s13550-025-01217-7
8. Volume of the proximal half of the thoracic aorta is the most comprehensive FDG-PET/CT indicator of arterial aging throughout adulthood.
   Hurstel M, Joly L, Imbert L, Zimmermann G, et al · · 2023 · PMID 37369917 · DOI 10.1186/s41824-023-00169-2